Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ME2 | P23368 | 1/20 | 0.41 |
| ▸ | ME1 | P48163 | 1/20 | 0.41 |
| ▸ | ME3 | Q16798 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600744 | 0.90 | HRH3 (0.46) | HRH3OGANPC1RAB9AKMT2A | |
| SCHEMBL19580874 | 0.82 | SMO (0.51) | HRH3OGADGAT1NPC1RAB9A | |
| SCHEMBL19600751 | 0.78 | HRH3 (0.56) | HRH3NPC1RAB9AKMT2A | |
| SCHEMBL19601033 | 0.78 | HRH3 (0.56) | HRH3NPC1RAB9AKMT2A | |
| SCHEMBL19581011 | 0.78 | OGA (0.48) | HRH3OGANPC1RAB9AKMT2A | |
| SCHEMBL29817233 | 0.78 | OGA (0.48) | HRH3OGANPC1RAB9AKMT2A | |
| SCHEMBL19598759 | 0.76 | HRH3 (0.52) | HRH3NPC1RAB9AKMT2AME2 | |
| SCHEMBL7331983 | 0.75 | TSHR (0.59) | NPC1RAB9AKMT2AME2ME1 | |
| SCHEMBL7333300 | 0.75 | TSHR (0.59) | NPC1RAB9AKMT2AME2ME1 | |
| SCHEMBL19581023 | 0.73 | KMT2A (0.50) | HRH3NPC1RAB9AKMT2AME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HRH3 3784/4885OGA 681/4885DGAT1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.